Your browser doesn't support javascript.
loading
Reduced binding of apoE4 to complement factor H promotes amyloid-ß oligomerization and neuroinflammation.
Chernyaeva, Larisa; Ratti, Giorgio; Teirilä, Laura; Fudo, Satoshi; Rankka, Uni; Pelkonen, Anssi; Korhonen, Paula; Leskinen, Katarzyna; Keskitalo, Salla; Salokas, Kari; Gkolfinopoulou, Christina; Crompton, Katrina E; Javanainen, Matti; Happonen, Lotta; Varjosalo, Markku; Malm, Tarja; Leinonen, Ville; Chroni, Angeliki; Saavalainen, Päivi; Meri, Seppo; Kajander, Tommi; Wollman, Adam Jm; Nissilä, Eija; Haapasalo, Karita.
Afiliación
  • Chernyaeva L; Department of Bacteriology and Immunology, Medicum and Human Microbiome Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
  • Ratti G; Humanitas University, Milano, Italy.
  • Teirilä L; Department of Bacteriology and Immunology, Medicum and Human Microbiome Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
  • Fudo S; Department of Bacteriology and Immunology, Medicum and Human Microbiome Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
  • Rankka U; Department of Bacteriology and Immunology, Medicum and Human Microbiome Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
  • Pelkonen A; A.I. Virtanen Institute for Molecular Sciences, Faculty of Health Sciences, University of Eastern Finland, Kuopio, Finland.
  • Korhonen P; A.I. Virtanen Institute for Molecular Sciences, Faculty of Health Sciences, University of Eastern Finland, Kuopio, Finland.
  • Leskinen K; Department of Bacteriology and Immunology, Medicum and Human Microbiome Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
  • Keskitalo S; Institute of Biotechnology, HiLIFE Helsinki Institute of Life Science, University of Helsinki, Helsinki, Finland.
  • Salokas K; Institute of Biotechnology, HiLIFE Helsinki Institute of Life Science, University of Helsinki, Helsinki, Finland.
  • Gkolfinopoulou C; Institute of Biosciences and Applications, National Center for Scientific Research "Demokritos", Athens, Greece.
  • Crompton KE; Biosciences Institute, Newcastle University, Newcastle-Upon-Tyne, UK.
  • Javanainen M; Institute of Biotechnology, HiLIFE Helsinki Institute of Life Science, University of Helsinki, Helsinki, Finland.
  • Happonen L; Division of Infection Medicine, Department of Clinical Sciences, Lund University, Lund, Sweden.
  • Varjosalo M; Institute of Biotechnology, HiLIFE Helsinki Institute of Life Science, University of Helsinki, Helsinki, Finland.
  • Malm T; A.I. Virtanen Institute for Molecular Sciences, Faculty of Health Sciences, University of Eastern Finland, Kuopio, Finland.
  • Leinonen V; Institute of Clinical Medicine - Neurosurgery, University of Eastern Finland and Department of Neurosurgery, Kuopio University Hospital, Kuopio, Finland.
  • Chroni A; Institute of Biosciences and Applications, National Center for Scientific Research "Demokritos", Athens, Greece.
  • Saavalainen P; Department of Bacteriology and Immunology, Medicum and Human Microbiome Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
  • Meri S; Department of Bacteriology and Immunology, Medicum and Human Microbiome Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
  • Kajander T; Humanitas University, Milano, Italy.
  • Wollman AJ; Institute of Biotechnology, HiLIFE Helsinki Institute of Life Science, University of Helsinki, Helsinki, Finland.
  • Nissilä E; Biosciences Institute, Newcastle University, Newcastle-Upon-Tyne, UK.
  • Haapasalo K; Department of Bacteriology and Immunology, Medicum and Human Microbiome Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
EMBO Rep ; 24(7): e56467, 2023 Jul 05.
Article en En | MEDLINE | ID: mdl-37155564
ABSTRACT
The APOE4 variant of apolipoprotein E (apoE) is the most prevalent genetic risk allele associated with late-onset Alzheimer's disease (AD). ApoE interacts with complement regulator factor H (FH), but the role of this interaction in AD pathogenesis is unknown. Here we elucidate the mechanism by which isoform-specific binding of apoE to FH alters Aß1-42-mediated neurotoxicity and clearance. Flow cytometry and transcriptomic analysis reveal that apoE and FH reduce binding of Aß1-42 to complement receptor 3 (CR3) and subsequent phagocytosis by microglia which alters expression of genes involved in AD. Moreover, FH forms complement-resistant oligomers with apoE/Aß1-42 complexes and the formation of these complexes is isoform specific with apoE2 and apoE3 showing higher affinity to FH than apoE4. These FH/apoE complexes reduce Aß1-42 oligomerization and toxicity, and colocalize with complement activator C1q deposited on Aß plaques in the brain. These findings provide an important mechanistic insight into AD pathogenesis and explain how the strongest genetic risk factor for AD predisposes for neuroinflammation in the early stages of the disease pathology.
Asunto(s)
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Apolipoproteína E4 / Enfermedad de Alzheimer Tipo de estudio: Risk_factors_studies Límite: Humans Idioma: En Revista: EMBO Rep Asunto de la revista: BIOLOGIA MOLECULAR Año: 2023 Tipo del documento: Article País de afiliación: Finlandia

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Apolipoproteína E4 / Enfermedad de Alzheimer Tipo de estudio: Risk_factors_studies Límite: Humans Idioma: En Revista: EMBO Rep Asunto de la revista: BIOLOGIA MOLECULAR Año: 2023 Tipo del documento: Article País de afiliación: Finlandia